Stryker (NYSE: SYK) today announced the launch of its recently FDA-cleared Incompass total ankle system.
Portage, Michigan–based Stryker received FDA 510(k) clearance for Incompass in June. It intends to begin the launch at the 2025 AOFAS Annual Meeting in Savannah, Georgia, this week.
Incompass — cleared for patients with end-stage ankle arthritis — introduces an innovative implant with an enhanced instrument platform. The orthopedic giant designed the implant for patients with ankle joints damaged by severe rheumatoid, post-traumatic or degenerative arthritis. The company says its new platform integrates the technologies of its Inbone and Infinity systems into a single, comprehensive system.
Stryker said the system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real-time. It features 3D-printed porous metal tibial and talar components engineered to promote bony ingrowth. By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands, Stryker says.
Adam Jacobs, VP and GM of Stryker’s Foot & Ankle business, said Stryker developed the system with one goal in mind. It aimed to give surgeons more flexibility and confidence while improving outcomes for patients.
“This advanced system has been fully reimagined by the insights of countless surgeons, engineers, and real-world use cases built on 20 years of experience,” Jacobs said. “We’re proud to continue leading the way in total ankle innovation and help shape what’s next for ankle arthroplasty.”
